ARCHIVES

FDA Grants Six-Month Priority Review To Nolvadex For DCIS Adjuvant Treatment.

This article is from The Cancer Letter archive.

Vol. 26 No. 13 | March 31, 2000

Download PDF Visit The Full Archive

Related Articles

In Congress; Senate Ok’s $185 Mil. Addition For Breast Cancer

October 2, 1992

FDA News: FDA Approves Reagent System for Graft-Versus-Host Disease

January 24, 2014

Risks Of Long-Term HRT Outweigh Benefits, WHI Finds

March 28, 2008

FDA’s Commitment To Cancer No Different Than Other Diseases, Kessler Tells Advocate

August 14, 1992

Two Phase II Studies of Ibrutinib Deliver High Response Rates

December 27, 2013

Senate Committee Approves Additional $400 Million For NCI, $275 Million For FDA.

May 16, 2008